You just read:

Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium

News provided by

Boston Biomedical, Inc.

21 Jan, 2017, 10:00 ET